| Popis: |
The COVID-19 outbreak, caused by the severe acute respiratory syndrome coronavirus 2, has been detected in December 2019 in Wuhan, China, and is accompanied by significant degrees of morbidity and mortality. Antibiotic resistance (AMR) threatens to wreak havoc on healthcare system and the impact of globalization, and COVID-19 is intended to keep it at bay for the time being. During the COVID-19 crisis, a wide range of antimicrobial medicines were promoted as viable treatments. While both industrialized and industrializing nations have seen a rise in antimicrobial medication usage, use and abuse have been significantly more prevalent in developing countries. Antibiotic resistance is still a concern since microorganisms that cause resistant infections develop in hospitals and medical institutions, placing all patients at risk, complicating the care of COVID-19. Improper prescriptions, a lack of care management policies and needless self-administration by the general population are examples of these. Antibiotics seem to be more motivated to abuse and misusing antibiotics than to keep them safe and take them only when prescribed. Almost all of the substantial antibiotic usage in COVID-19 patients is inevitable. Patients having lung viral infections are more likely to develop subsequent bacterial infections, which lead to higher disease severity and death. Immediately crucial components of any AMR mitigation approach are increased spending in education and increased public knowledge of AMR. More studies are needed to better understand the health risks and rate of co-infection in COVID-19 patients in order to promote a decrease in any unnecessary antimicrobial prescribing. Keywords: COVID-19; Antibiotic use and misuse; Antimicrobial Resistance. |
